FTRE

Fortrea is a ~$2.7B-revenue contract research organization spun out of Labcorp in mid-2023, and the FY2025 numbers show a business still searching for its footing as a standalone. The headline -$986M net loss looks catastrophic, but it is dominated by a non-cash $797.9M goodwill impairment specific to the Clinical Development reporting unit (per the MD&A). Strip that out and operating income is roughly breakeven-to-slightly-negative — the company is not bleeding cash. In fact operating cash flow was positive at $114M, cash rose 47% to $175M, and interest expense fell 26% to $91.4M as they paid down term debt. That is a stabilizing, deleveraging story, not a collapse.

The trouble is what the impairment signals: management wrote down the value of the core clinical-development franchise, and the MD&A admits revenue there fell on an unfavorable mix of complex/longer-duration studies and lower FSP volume. Organic growth was just 0.8%, and revenue has drifted down from $3.06B in 2021 to $2.72B in 2025 — five years of stagnation-to-decline while peers in the CRO space have grown. Worse, direct costs rose to 81.5% of revenue from 80.2%, so the operating model is getting less efficient, not more. ROE of -175% and an accumulated deficit of -$1.38B reflect a company that has destroyed equity since the spin.